May 14, 2015
Takeda Pharmaceutical said on May 13 that it has decided to call off a PIII clinical study of its investigational Aurora A kinase inhibitor alisertib (development code: MLN8237) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The decision...read more